Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALXO ALX Oncology	$0.45 -1.1%	$0.50	$0.41 ▼ $8.78	$24.44M	1.16	925,115 shs	220,362 shs
DYAI Dyadic International	$1.00 +1.2%	$1.06	$0.91 ▼ $2.20	$29.58M	0.92	54,514 shs	33,732 shs
JBIO Jade Biosciences	$9.25 -12.0%	$0.00	$6.57 ▼ $105.00	$8.83M	0.93	477,362 shs	243,176 shs
KALA KALA BIO	$5.26 +11.9%	$3.86	$2.92 ▼ $11.20	$30.33M	-1.98	96,310 shs	138,046 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALXO ALX Oncology	-1.11%	-6.97%	+0.96%	-30.91%	-92.30%
DYAI Dyadic International	+1.21%	+0.51%	+5.85%	-27.37%	-41.47%
JBIO Jade Biosciences	-11.99%	-1.70%	+924,999,900.00%	+924,999,900.00%	+924,999,900.00%
KALA KALA BIO	+11.91%	+24.06%	+29.56%	-13.06%	+14.35%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALXO ALX Oncology	2.5897 of 5 stars	3.4	1.0	0.0	1.6	3.3	1.3
DYAI Dyadic International	2.2755 of 5 stars	3.5	2.0	0.0	3.3	1.7	0.0
JBIO Jade Biosciences	2.4296 of 5 stars	3.5	0.0	0.0	2.7	1.7	0.6
KALA KALA BIO	3.9127 of 5 stars	3.5	1.0	4.4	3.3	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALXO ALX Oncology	2.71	Moderate Buy	$3.30	629.12% Upside
DYAI Dyadic International	3.00	Buy	$6.00	503.02% Upside
JBIO Jade Biosciences	3.00	Buy	$14.00	51.35% Upside
KALA KALA BIO	3.00	Buy	$13.50	156.65% Upside

Current Analyst Ratings Breakdown

Latest JBIO, DYAI, KALA, and ALXO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	JBIO Jade Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$14.00
6/2/2025	KALA KALA BIO	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$15.00
5/23/2025	KALA KALA BIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00
5/21/2025	ALXO ALX Oncology	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$1.20 ➝ $1.00
5/9/2025	ALXO ALX Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $2.00
4/4/2025	KALA KALA BIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALXO ALX Oncology	N/A	N/A	N/A	N/A	$2.14 per share	N/A
DYAI Dyadic International	$3.49M	8.58	N/A	N/A	$0.08 per share	12.44
JBIO Jade Biosciences	N/A	N/A	N/A	N/A	$92.88 per share	N/A
KALA KALA BIO	$3.89M	8.72	N/A	N/A	$2.02 per share	2.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALXO ALX Oncology	-$134.85M	-$2.47	N/A	N/A	N/A	N/A	-104.43%	-77.74%	8/6/2025 (Estimated)
DYAI Dyadic International	-$5.81M	-$0.20	N/A	N/A	N/A	-163.94%	-233.69%	-59.37%	8/12/2025 (Estimated)
JBIO Jade Biosciences	-$69.63M	-$59.65	N/A	∞	N/A	N/A	-60.01%	-54.32%	N/A
KALA KALA BIO	-$38.51M	-$8.24	N/A	N/A	N/A	N/A	-369.29%	-64.99%	8/5/2025 (Estimated)

Latest JBIO, DYAI, KALA, and ALXO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	DYAI Dyadic International	N/A	-$0.07	N/A	-$0.07	N/A	$0.39 million
5/8/2025	Q1 2025	ALXO ALX Oncology	-$0.47	-$0.58	-$0.11	-$0.58	N/A	N/A
3/28/2025	Q4 2024	KALA KALA BIO	-$2.28	-$1.74	+$0.54	-$1.74	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALXO ALX Oncology	N/A	N/A	N/A	N/A	N/A
DYAI Dyadic International	N/A	N/A	N/A	N/A	N/A
JBIO Jade Biosciences	N/A	N/A	N/A	N/A	N/A
KALA KALA BIO	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALXO ALX Oncology	0.09	5.47	5.47
DYAI Dyadic International	5.40	3.98	3.98
JBIO Jade Biosciences	N/A	32.01	32.01
KALA KALA BIO	3.19	1.99	1.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALXO ALX Oncology	97.97%
DYAI Dyadic International	27.95%
JBIO Jade Biosciences	N/A
KALA KALA BIO	24.61%

Insider Ownership

Company	Insider Ownership
ALXO ALX Oncology	21.00%
DYAI Dyadic International	29.50%
JBIO Jade Biosciences	24.90%
KALA KALA BIO	8.32%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALXO ALX Oncology	40	53.40 million	42.18 million	Optionable
DYAI Dyadic International	7	30.09 million	21.21 million	Optionable
JBIO Jade Biosciences	20	840,000	632,000	N/A
KALA KALA BIO	30	6.45 million	5.92 million	Not Optionable

JBIO, DYAI, KALA, and ALXO Headlines

Recent News About These Companies

KALA BIO, Inc. (NASDAQ:KALA) CFO Sells $14,560.31 in Stock

1 hour ago | insidertrades.com

Mary Reumuth Sells 2,850 Shares of KALA BIO, Inc. (NASDAQ:KALA) Stock

June 5, 2025 | insidertrades.com

KALA BIO to Present at Jefferies Global Healthcare Conference

May 29, 2025 | globenewswire.com

KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025 | finance.yahoo.com

Chief Minister cancels programme over unauthorised nature of venue

April 20, 2025 | thehindu.com

KALA BIO: Q4 Earnings Snapshot

March 31, 2025 | timesunion.comT

KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

March 31, 2025 | markets.businessinsider.com

KALA BIO to Present at TD Cowen 45th Annual Health Care Conference

February 26, 2025 | finance.yahoo.com

Kala Bio announces CEO departure, appoints interim leader

February 12, 2025 | msn.com

KALA BIO, Inc.: KALA BIO Announces Chief Executive Officer Transition

February 12, 2025 | finanznachrichten.de

Kala Bio appoints new interim CEO amid leadership shuffle

February 12, 2025 | msn.com

Kala announces resignation of CEO Iwicki, Bazemore appointed interim CEO

February 12, 2025 | markets.businessinsider.com

Kala Bio Stock Sinks On CEO Exit, But Retail Feels It’s An Overreaction

February 12, 2025 | msn.com

KALA BIO Announces Chief Executive Officer Transition

February 12, 2025 | globenewswire.com

KALA stock soars to 52-week high, reaching $8.81

January 29, 2025 | msn.com

Kala Pharmaceuticals files to sell 1.67M shares of common stock for holders

January 24, 2025 | markets.businessinsider.com

KALA BIO, Inc. (NASDAQ:KALA) CFO Sells $13,016.78 in Stock

January 8, 2025 | insidertrades.com

Bros. Advisors Lp Baker Purchases 310,559 Shares of KALA BIO, Inc. (NASDAQ:KALA) Stock

January 1, 2025 | insidertrades.com

KALA BIO, Inc. Secures $10.75 Million in Private Placement to Advance Clinical Development of KPI-012

December 30, 2024 | quiverquant.comQ

KALA BIO Announces $10,750,000 Private Placement

December 30, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JBIO, DYAI, KALA, and ALXO Company Descriptions

ALX Oncology NASDAQ:ALXO

$0.45 -0.01 (-1.11%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$0.46 +0.01 (+1.63%)

As of 07:00 AM Eastern

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Dyadic International NASDAQ:DYAI

$1.00 +0.01 (+1.21%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$0.99 -0.01 (-0.70%)

As of 07:00 AM Eastern

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Jade Biosciences NASDAQ:JBIO

$9.25 -1.26 (-11.99%)

As of 06/26/2025 04:00 PM Eastern

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

KALA BIO NASDAQ:KALA

$5.26 +0.56 (+11.91%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$5.28 +0.02 (+0.30%)

As of 08:03 AM Eastern

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time